Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. It is primarily expressed on mature B lymphocytes, plasmablasts, and plasma cells. BCMA plays a crucial role in the survival of long-lived plasma cells and is a key therapeutic target in multiple myeloma due to its overexpression on malignant plasma cells. Ligands BAFF and APRIL bind to BCMA, activating intracellular signaling pathways that promote cell survival and proliferation. Soluble BCMA can be found in blood due to cleavage by γ-secretase.
Ligand binding (BAFF, APRIL) activates intracellular signaling pathways (NF-kappaB, MEK/ERK, AKT, JNK, p38 kinase) promoting cell survival and proliferation; therapeutic targeting aims to induce cell death in BCMA-expressing cells via various mechanisms (T-cell mediated lysis, direct cytotoxicity)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell maturation antigen (BCMA).